A new study published in Cancer Research concluded that the recurrence of hormone related breast cancer was cut in half in overweight and obese women who regularly used aspirin or other non steroidal anti-inflammatory drugs (NSAID’s). authors said “Our study suggests that limiting inflammatory signaling may be effective, less toxic approach to altering the cancer promiting effects of obesity and improving patient response to hormonal therapy.” In their study researchers fround that women whose body mass index was greater than 30 and had estrogen receptor alpha (ERa) -positive breast cancer had a 52 percent lower rate of occurrence and a 28-month delay in time of recurrence if they were taking aspirin or other NSAID’s. Using blood from obese patients, researchers carried out laboratory experiments to recreate atumor environment containing cancer cells, fat cells, and the immune cells that promote inflammation. They found that factors associated with obesity initiate a network of signaling within the tumor environment to promote growth and resistance to therapy. They concluded “These studies show that the greatest benefit from aspirin and other NSAID’s will be in those with a disease driven by inflammation , and not just obesity.”
Data was used from 440 women diagnosed with invasive ERa-positive breast cancer and treatedbetween 1987 and 2011. Of the group studies 48.5 percent were obese and 25,8 percent were overweight. About 81 percent took aspirin, and the rest took another NSAID. About 42 percent and 25 percent took statins and omega-3 fatty acid respectively. After controlling for statin and omega-3 fatty acids that have anti-inflammatory effects, there was still an indication of protection from aspirin and other NSAID’s.